Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy.

Authors: Boz Er, Asiye Busra¹ (AUTHOR) asiyebusra.bozer@erdogan.edu.tr, Sheldrake, Helen M.¹ (AUTHOR) h.sheldrake@bradford.ac.uk, Sutherland, Mark² (AUTHOR) h.sheldrake@bradford.ac.uk

Source: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7946. 23p.

Subject Terms: *VEMURAFENIB, *BRAF genes, *INTEGRINS, *MELANOMA, *TREATMENT effectiveness, *SKIN cancer, *NATALIZUMAB, *CETUXIMAB

Correction: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.

Authors: Hao, Jiaojiao¹ (AUTHOR), Fan, Wenhua² (AUTHOR), Li, Yizhuo² (AUTHOR), Tang, Ranran³ (AUTHOR), Tian, Chunfang¹ (AUTHOR), Yang, Qian¹ (AUTHOR), Zhu, Tianhua¹ (AUTHOR), Diao, Chaoliang¹ (AUTHOR), Hu, Sheng¹ (AUTHOR), Chen, Manyu¹ (AUTHOR), Guo, Ping¹ (AUTHOR), Long, Qian² (AUTHOR), Zhang, Changlin² (AUTHOR), Qin, Ge² (AUTHOR), Yu, Wendan¹ (AUTHOR), Chen, Miao² (AUTHOR), Li, Liren² (AUTHOR), Qin, Lijun⁴ (AUTHOR), Wang, Jingshu⁴ (AUTHOR), Zhang, Xiuping⁵ (AUTHOR)

Source: Journal of Experimental & Clinical Cancer Research (17569966). 6/26/2024, Vol. 43 Issue 1, p1-5. 5p.

Subject Terms: *VEMURAFENIB, *MELANOMA, *CELL communication, *STREPTAVIDIN, *MELATONIN

MitoCur‐1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14.

Authors: Li, Gege¹ (AUTHOR), Zhou, Changlong¹ (AUTHOR), Wang, Lu^2,3 (AUTHOR), Zheng, Yalong⁴ (AUTHOR), Zhou, Bo⁴ (AUTHOR), Li, Guoyan¹ (AUTHOR), Ma, Zhongyu¹ (AUTHOR), Sun, Peng⁵ (AUTHOR), Deng, Yuantao⁶ (AUTHOR), Su, Li¹ (AUTHOR), Wang, Junling¹ (AUTHOR) wangjl@lzu.edu.cn, Cui, Hongmei¹ (AUTHOR) cuihm@lzu.edu.cn

Source: Pigment Cell & Melanoma Research. Mar2024, Vol. 37 Issue 2, p316-328. 13p.

Subject Terms: *DEUBIQUITINATING enzymes, *VEMURAFENIB, *BRAF genes, *MELANOMA, *UBIQUITIN ligases, *ENZYME inactivation, *TUBULINS

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Authors: Dummer, Reinhard^1,2 (AUTHOR) reinhard.dummer@usz.ch, Welti, Michèle^1,2 (AUTHOR), Ramelyte, Egle^1,2 (AUTHOR)

Source: Journal of Translational Medicine. 8/5/2023, Vol. 21 Issue 1, p1-5. 5p.

Subject Terms: *BRAF genes, *VEMURAFENIB, *OVERALL survival, *ATEZOLIZUMAB, *MELANOMA, *PROGRESSION-free survival, *METASTASIS

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.

Authors: Tóvári, József^1,2 (AUTHOR), Vári-Mező, Diána^1,2 (AUTHOR), Surguta, Sára Eszter^1,2 (AUTHOR), Ladányi, Andrea^2,3 (AUTHOR) ladanyi.andrea@oncol.hu, Kigyós, Attila⁴ (AUTHOR) info@kinetolab.hu, Cserepes, Mihály^1,2 (AUTHOR) cserepestm@oncol.hu

Source: Cells (2073-4409). Jul2023, Vol. 12 Issue 14, p1919. 19p.

Subject Terms: *VEMURAFENIB, *BRAF genes, *MELANOMA, *IMMUNOREGULATION, *P-glycoprotein, *CELL death

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.

Authors: Żołek, Teresa¹ (AUTHOR) tzolek@wum.edu.pl, Mazurek, Adam² (AUTHOR), Grudzinski, Ireneusz P.² (AUTHOR) tzolek@wum.edu.pl

Source: Molecules. Jul2023, Vol. 28 Issue 13, p5273. 22p.

Subject Terms: *KINASE inhibitors, *VEMURAFENIB, *BRAF genes, *DENSITY functionals, *DENSITY functional theory

An effective treatment in Erdheim Chester disease: vemurafenib: a case report.

Authors: Bozan, Ersin¹ (AUTHOR) ersinbozan87@gmail.com, Darçın, Tahir¹ (AUTHOR), Yaman, Samet¹ (AUTHOR), Yiğenoğlu, Tuğçe Nur¹ (AUTHOR), Kızıl Çakar, Merih¹ (AUTHOR), Dal, Mehmet Sinan¹ (AUTHOR), Altuntaş, Fevzi¹ (AUTHOR)

Source: Journal of Medical Case Reports. 10/12/2023, Vol. 17 Issue 1, p1-3. 3p.

Subject Terms: *ERDHEIM-Chester disease, *VEMURAFENIB, *NON-langerhans-cell histiocytosis, *BRAF genes, *WOMEN patients, *KNEE pain

Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.

Authors: Mohapatra, Debabrata¹ (AUTHOR), Gupta, Aditya Kumar¹ (AUTHOR), Haldar, Partha² (AUTHOR), Meena, Jagdish Prasad¹ (AUTHOR), Tanwar, Pranay³ (AUTHOR), Seth, Rachna¹ (AUTHOR)

Source: Pediatric Hematology & Oncology. Feb2023, Vol. 40 Issue 1, p86-97. 12p.

Subject Terms: *LANGERHANS-cell histiocytosis, *VEMURAFENIB, *INDUCTION chemotherapy, *TREATMENT duration

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.

Authors: Li, Qingqing¹ (AUTHOR) li1611817362@qq.com

Source: Journal of Dermatological Treatment. 2023, Vol. 34 Issue 1, p1-5. 5p.

Subject Terms: *LANGERHANS-cell histiocytosis, *VEMURAFENIB, *TREATMENT effectiveness, *INFANTS, *ERDHEIM-Chester disease

Vemurafenib Inhibits Enterovirus A71 Genome Replication and Virus Assembly.

Authors: Hu, Bodan¹ (AUTHOR), Chik, Kenn Ka-Heng^1,2 (AUTHOR), Chan, Jasper Fuk-Woo^1,2,3 (AUTHOR), Cai, Jian-Piao¹ (AUTHOR), Cao, Hehe¹ (AUTHOR), Tsang, Jessica Oi-Ling^1,2 (AUTHOR), Zou, Zijiao¹ (AUTHOR), Hung, Yin-Po¹ (AUTHOR), Tang, Kaiming¹ (AUTHOR), Jia, Lilong¹ (AUTHOR), Luo, Cuiting¹ (AUTHOR), Yin, Feifei^3,4 (AUTHOR), Ye, Zi-Wei⁵ (AUTHOR), Chu, Hin^1,2 (AUTHOR), Yeung, Man-Lung^1,2 (AUTHOR), Yuan, Shuofeng^1,2 (AUTHOR) yuansf@hku.hk

Source: Pharmaceuticals (14248247). Sep2022, Vol. 15 Issue 9, pN.PAG-N.PAG. 11p.

Subject Terms: *ENTEROVIRUSES, *VEMURAFENIB, *VIRAL replication, *REGULATION of growth, *CELLULAR control mechanisms, *GENOMES, *BRAF genes

SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib.

Authors: Kretschmer, Nadine^1,2 (AUTHOR) beate.rinner@medunigraz.at, Durchschein, Christin¹ (AUTHOR) christin.durchschein@hotmail.com, Hufner, Antje³ (AUTHOR) antje.huefner@uni-graz.at, Rinner, Beate² (AUTHOR), Lohberger, Birgit⁴ (AUTHOR) birgit.lohberger@medunigraz.at, Bauer, Rudolf¹ (AUTHOR) rudolf.bauer@uni-graz.at

Source: International Journal of Molecular Sciences. May2022, Vol. 23 Issue 10, p5684-5684. 15p.

Subject Terms: *SHIKONIN, *VEMURAFENIB, *CELL lines, *MELANOMA, *CELL death, *MELANOGENESIS

Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib.

Authors: Trambusti, Irene¹ (AUTHOR), Pegoraro, Francesco^1,2 (AUTHOR), Gaspari, Stefania³ (AUTHOR), Dell'Acqua, Fabiola⁴ (AUTHOR), Cellini, Monica⁵ (AUTHOR), Trizzino, Antonino⁶ (AUTHOR), Tondo, Annalisa¹ (AUTHOR), Perrone, Anna⁷ (AUTHOR), Coniglio, Maria Luisa¹ (AUTHOR), Guerrini, Renzo^8,9 (AUTHOR), Barba, Carmen^8,9 (AUTHOR), Sieni, Elena¹ (AUTHOR) elena.sieni@meyer.it

Source: British Journal of Haematology. Jun2024, Vol. 204 Issue 6, p2508-2511. 4p.

Subject Terms: *LANGERHANS-cell histiocytosis, *VEMURAFENIB, *DIABETES insipidus, *AUDITORY evoked response

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.

Authors: Shi, Yuankai¹ (AUTHOR) syuankai@cicams.ac.cn, Han, Xiaohong² (AUTHOR), Zhao, Qian² (AUTHOR), Zheng, YuLong³ (AUTHOR), Chen, Jianhua⁴ (AUTHOR), Yu, Xinmin⁵ (AUTHOR), Fang, Jian⁶ (AUTHOR), Liu, Yutao¹ (AUTHOR), Huang, Dingzhi⁷ (AUTHOR), Liu, Tianshu⁸ (AUTHOR), Shen, Hong⁹ (AUTHOR), Luo, Suxia¹⁰ (AUTHOR), Yu, Hongsheng¹¹ (AUTHOR), Cao, Yu¹² (AUTHOR), Zhang, Xi¹³ (AUTHOR), Hu, Pei² (AUTHOR)

Source: Experimental Hematology & Oncology. 6/12/2024, Vol. 13 Issue 1, p1-12. 12p.

Subject Terms: *VEMURAFENIB, *BRAF genes, *NON-small-cell lung carcinoma, *PROGRESSION-free survival, *CREATINE kinase

Cholesterol neutralized vemurafenib treatment by promoting melanoma stem-like cells via its metabolite 27-hydroxycholesterol.

Authors: Wang, Xiaohong^1,2 (AUTHOR), Zhong, Feiliang³ (AUTHOR), Chen, Tingting⁴ (AUTHOR), Wang, Hongbo^1,2 (AUTHOR), Wang, Weifang^1,2 (AUTHOR), Jin, Hongkai¹ (AUTHOR), Li, Chouyang² (AUTHOR), Guo, Xuan^1,2 (AUTHOR), Liu, Ying^1,2 (AUTHOR), Zhang, Yu^1,2 (AUTHOR) zhangyu007@hsc.pku.edu.cn, Li, Bo^1,2 (AUTHOR) libo0628@jzmu.edu.cn

Source: Cellular & Molecular Life Sciences. 5/22/2024, Vol. 81 Issue 1, p1-19. 19p.

Subject Terms: *MELANOMA, *VEMURAFENIB, *CHOLESTEROL, *CYTOCHROME P-450, *HYDROXYCHOLESTEROLS, *OVERALL survival

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.

Authors: Ainiwan, Yilamujiang, Li, Haomin, Zheng, Yongjia, Wei, Songtao, Peng, Junxiang, Nie, Jing, Mao, Chaofu, Chen, Kunxiang, Chen, Siyuan, Liu, Ningyuan, Li, Can, Chen, Yan, Qu, Shanqiang, Wang, Yunji, Zhou, Mingfeng, Mao, Jian, Mei, Fen, Chen, Jingting, Song, Qiancheng, Qi, Songtao

Source: Acta Neuropathologica Communications; 3/3/2025, Vol. 13 Issue 1, p1-13, 13p

Subject Terms: MEDICAL sciences, ANLOTINIB, NEOVASCULARIZATION inhibitors, LABORATORY mice, VEMURAFENIB

Durable Remission After Targeted Therapy in BRAF V600E--Mutant Metastatic Colorectal Cancer: Case Report.

Authors: Fox, Daniel A., Bhamidipati, Deepak, Kopetz, Scott, Hong, David S.

Source: Journal of Immunotherapy & Precision Oncology; Feb2025, Vol. 8 Issue 1, p11-14, 4p

Subject Terms: COLORECTAL cancer, BRAF genes, VEMURAFENIB, METASTASIS, DISEASE progression

Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma Patients—A Case Report.

Authors: Veljovic, Tanja, Djuric, Milanko, Gusic, Ivana, Vuckovic, Nada, Ramic, Bojana, Mirnic, Jelena

Source: Journal of Clinical Medicine; Jan2025, Vol. 14 Issue 1, p65, 9p

Subject Terms: GINGIVAL hyperplasia, PATIENT compliance, GINGIVAL hemorrhage, ORAL hygiene, VEMURAFENIB

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation

Authors: Yilamujiang Ainiwan, Haomin Li, Yongjia Zheng, Songtao Wei, Junxiang Peng, Jing Nie, Chaofu Mao, Kunxiang Chen, Siyuan Chen, Ningyuan Liu, Can Li, Yan Chen, Shanqiang Qu, Yunji Wang, Mingfeng Zhou, Jian Mao, Fen Mei, Jingting Chen, Qiancheng Song, Songtao Qi, Jun Pan

Source: Acta Neuropathologica Communications, Vol 13, Iss 1, Pp 1-13 (2025)

Subject Terms: Papillary craniopharyngioma, BRAFv600e mutation, Calcification, Vemurafenib, Anlotinib, Neurology. Diseases of the nervous system, RC346-429

File Description: electronic resource

Relation: https://doaj.org/toc/2051-5960

Access URL: https://doaj.org/article/a96408f1177340a091c7b059f224ad11

Durable Remission After Targeted Therapy in BRAF V600E–Mutant Metastatic Colorectal Cancer: Case Report

Authors: Daniel A. Fox, Deepak Bhamidipati, Scott Kopetz, David S. Hong

Source: Journal of Immunotherapy and Precision Oncology, Vol 8, Iss 1, Pp 11-14 (2025)

Subject Terms: vemurafenib, braf v600e, colorectal cancer, dmmr, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://doaj.org/toc/2666-2345; https://doaj.org/toc/2590-017X

Access URL: https://doaj.org/article/7c5719e50537416e96c1c40838b2df4f

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts.

Authors: Corrales, Eyleen^1,2,3 (AUTHOR), Levit-Zerdoun, Ella^1,2,4 (AUTHOR), Metzger, Patrick² (AUTHOR), Kowar, Silke^1,2 (AUTHOR), Ku, Manching⁵ (AUTHOR), Brummer, Tilman^1,4,6,7 (AUTHOR), Boerries, Melanie^1,2,4,6,7 (AUTHOR) melanie.boerries@uniklinik-freiburg.de

Source: Cell Communication & Signaling. 12/20/2021, Vol. 19 Issue 1, p1-22. 22p.

Subject Terms: *VEMURAFENIB, *DRUG resistance in cancer cells, *TRANSCRIPTOMES, *DRUG resistance, *TRANSCRIPTION factors, *STROMAL cells